|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/30/20 Fuse Medical, Inc. 10-K 12/31/19 75:7.3M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 819K
2: EX-10.21 Material Contract HTML 30K
3: EX-21.1 Subsidiaries List HTML 21K
4: EX-23.1 Consent of Experts or Counsel HTML 23K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 30K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 30K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 27K
54: R1 Document and Entity Information HTML 83K
28: R2 Consolidated Balance Sheets HTML 100K
37: R3 Consolidated Balance Sheets (Parenthetical) HTML 46K
74: R4 Consolidated Statements of Operations HTML 83K
55: R5 Consolidated Statement of Changes in Stockholders' HTML 63K
Equity
29: R6 Consolidated Statements of Cash Flows HTML 103K
38: R7 Nature of Operations HTML 38K
72: R8 Significant Accounting Policies HTML 111K
57: R9 CPM Acquisition HTML 29K
49: R10 Maxim Acquisition HTML 56K
67: R11 Property and Equipment HTML 49K
34: R12 Goodwill and Intangible Assets HTML 80K
23: R13 Revolving Line of Credit HTML 32K
50: R14 Notes Payable - Related Parties HTML 26K
68: R15 Commitments and Contingencies HTML 41K
35: R16 Stockholders' Equity HTML 137K
24: R17 Income Taxes HTML 150K
48: R18 Concentrations HTML 64K
69: R19 Related Party Transactions HTML 56K
45: R20 Subsequent Events HTML 28K
18: R21 Significant Accounting Policies (Policies) HTML 164K
61: R22 Significant Accounting Policies (Tables) HTML 75K
65: R23 Maxim Acquisition (Tables) HTML 50K
46: R24 Property and Equipment (Tables) HTML 49K
19: R25 Goodwill and Intangible Assets (Tables) HTML 81K
62: R26 Commitments and Contingencies (Tables) HTML 38K
66: R27 Stockholders' Equity (Tables) HTML 134K
47: R28 Income Taxes (Tables) HTML 150K
17: R29 Concentrations (Tables) HTML 71K
21: R30 Nature of Operations (Details Narrative) HTML 42K
33: R31 Significant Accounting Policies (Details HTML 87K
Narrative)
71: R32 Significant Accounting Policies - Error Identified HTML 43K
in Weighted Average Number of Shares Outstanding
Used in Calculation of Earnings per Share
(Details)
52: R33 Significant Accounting Policies - Estimated Useful HTML 32K
Lives of Assets (Details)
20: R34 Significant Accounting Policies - Schedule of HTML 30K
Revenue Differentiation (Details)
32: R35 CPM Acquisition (Details Narrative) HTML 54K
70: R36 Maxim Acquisition (Details Narrative) HTML 49K
51: R37 Maxim Acquisition - Schedule of Unaudited Pro HTML 37K
Forma Information (Details)
22: R38 Property and Equipment - Summary of Property and HTML 39K
Equipment (Details)
31: R39 Property and Equipment (Details Narrative) HTML 27K
15: R40 Goodwill and Intangible Assets - Schedule of HTML 49K
Goodwill and Other Intangible Assets (Details)
44: R41 Goodwill and Intangible Assets - (Details HTML 29K
Narrative)
64: R42 Goodwill and Intangible Assets - Schedule of HTML 39K
Future Amortization Expense Related to Finite-Live
Intangible Assets (Details)
60: R43 Revolving Line of Credit (Details Narrative) HTML 97K
14: R44 Notes Payable - Related Parties (Details HTML 45K
Narrative)
43: R45 Commitments and Contingencies (Details Narrative) HTML 39K
63: R46 Commitments and Contingencies - Summary of HTML 35K
Operating Leases (Details)
59: R47 Stockholders' Equity - Summary of Compensation HTML 41K
Expense for Stock Options Granted to Board
Members, Employees And Marketing Representatives
(Details)
16: R48 Stockholders' Equity (Details Narrative) HTML 39K
41: R49 Stockholders' Equity - Summary of Stock Option HTML 57K
Activity (Details)
36: R50 Stockholders' Equity - Summary of Restricted Stock HTML 44K
Awards Activity (Details)
27: R51 Income Taxes - Components of Income Tax Expense HTML 45K
(Benefit) (Details)
53: R52 Income Taxes - Significant Components of Deferred HTML 62K
Income Tax Assets and Liabilities (Details)
73: R53 Income Taxes (Details Narrative) HTML 39K
39: R54 Income Taxes - Reconciliation of Income Tax HTML 40K
Computed at U.S. Statutory Rate to Effective
Income Tax Rate (Details)
30: R55 Concentrations - Significant Customers with HTML 31K
Individual Percentage of Total Revenues Equaling
Ten Percent (10%) or Greater (Details)
56: R56 Concentrations - Significant Customers with HTML 31K
Concentration of Accounts Receivable Representing
Ten Percent (10%) or Greater of Accounts
Receivable (Details)
75: R57 Concentrations - Significant Customers with HTML 31K
Concentration of Accounts Receivable Representing
Ten Percent (10%) or Greater of Accounts
Receivable (Parenthetical) (Details)
40: R58 Concentrations - Significant Suppliers Represented HTML 35K
Ten Percent (10%) or Greater of Goods Purchased
(Details)
26: R59 Related Party Transactions (Details Narrative) HTML 100K
25: XML IDEA XML File -- Filing Summary XML 135K
42: EXCEL IDEA Workbook of Financial Reports XLSX 80K
8: EX-101.INS XBRL Instance -- fzmd-20191231 XML 1.81M
10: EX-101.CAL XBRL Calculations -- fzmd-20191231_cal XML 152K
11: EX-101.DEF XBRL Definitions -- fzmd-20191231_def XML 566K
12: EX-101.LAB XBRL Labels -- fzmd-20191231_lab XML 1.25M
13: EX-101.PRE XBRL Presentations -- fzmd-20191231_pre XML 935K
9: EX-101.SCH XBRL Schema -- fzmd-20191231 XSD 179K
58: ZIP XBRL Zipped Folder -- 0001564590-20-014068-xbrl Zip 147K
Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
I, Christopher C. Reeg, certify that:
|
|
1. |
I have reviewed this annual report on Form 10-K of Fuse Medical, Inc.; |
|
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
|
4. |
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
|
a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
c) |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
d) |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
|
|
5. |
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|
|
a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
|
|
b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: March 30, 2020
|
Chief Executive Officer (Principal Executive Officer) |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/30/20 | None on these Dates | ||
| For Period end: | 12/31/19 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/14/23 Fuse Medical, Inc. 10-K 12/31/22 74:8.7M ActiveDisclosure/FA 3/31/22 Fuse Medical, Inc. 10-K 12/31/21 72:8.6M ActiveDisclosure/FA 3/31/21 Fuse Medical, Inc. 10-K 12/31/20 72:7.1M ActiveDisclosure/FA |